Erin Babcock, PhD

Inhibrx Biosciences, Inc.
La Jolla, California, United States

Presentation(s):

• Paper 31 - THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

  Friday, November 14, 2025
  8:30 AM - 10:00 AM EST

  Disclosure information not submitted.